CA2067205A1 - Vaccine and immune serum against drugs of abuse - Google Patents

Vaccine and immune serum against drugs of abuse

Info

Publication number
CA2067205A1
CA2067205A1 CA002067205A CA2067205A CA2067205A1 CA 2067205 A1 CA2067205 A1 CA 2067205A1 CA 002067205 A CA002067205 A CA 002067205A CA 2067205 A CA2067205 A CA 2067205A CA 2067205 A1 CA2067205 A1 CA 2067205A1
Authority
CA
Canada
Prior art keywords
drug
vaccine
drugs
immune serum
serum against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002067205A
Other languages
French (fr)
Other versions
CA2067205C (en
Inventor
Erich H. Cerny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHILKA Ltd
Original Assignee
Erich H. Cerny
Bio-Development Limited
Chilka Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4240096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2067205(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erich H. Cerny, Bio-Development Limited, Chilka Ltd. filed Critical Erich H. Cerny
Publication of CA2067205A1 publication Critical patent/CA2067205A1/en
Application granted granted Critical
Publication of CA2067205C publication Critical patent/CA2067205C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Addictive drugs like cocaine, heroin or amphetamines are spreading in an epidemic manner in the western world and are an important factor in the spread of the acquired immune deficiency syndrome AIDS(multiple use of infected needles among drug addicts). The present invention describes a vaccine and immune serum against drugs. The vaccine contains the drug bound to a carrier protein in order to produce antibodies against the drugs in the affected person. The use of the drug in the presence of the antibodies deactivates the drug. The desired drug effect is thus eliminated and the vicious circle between stimulation and application is broken.
CA002067205A 1990-08-22 1991-01-17 Vaccine and immune serum against drugs of abuse Expired - Lifetime CA2067205C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH2720/90A CH678394A5 (en) 1990-08-22 1990-08-22
CH2720/90-7 1990-08-22
PCT/CH1991/000016 WO1992003163A1 (en) 1990-08-22 1991-01-17 Vaccine and immunoserum against drugs of abuse

Publications (2)

Publication Number Publication Date
CA2067205A1 true CA2067205A1 (en) 1992-02-23
CA2067205C CA2067205C (en) 2009-10-27

Family

ID=4240096

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002067205A Expired - Lifetime CA2067205C (en) 1990-08-22 1991-01-17 Vaccine and immune serum against drugs of abuse

Country Status (8)

Country Link
EP (1) EP0496839B2 (en)
JP (1) JPH05502871A (en)
AT (1) ATE137977T1 (en)
AU (1) AU7050091A (en)
CA (1) CA2067205C (en)
CH (1) CH678394A5 (en)
DE (1) DE59107814D1 (en)
WO (1) WO1992003163A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210677B1 (en) 1993-01-29 2001-04-03 Robert C. Bohannon Method to reduce the physiologic effects of drugs on mammals
EP1175912A1 (en) * 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5773003A (en) * 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
ES2210356T3 (en) * 1995-03-31 2004-07-01 Xenova Research Limited HAPTAN-CARRIER CONJUGATES FOR EMPLOYMENT IN THERAPY AGAINST DRUG USE
AU776410B2 (en) * 1995-03-31 2004-09-09 Xenova Research Limited Hapten-carrier conjugates for use in drug-abuse therapy
US6063908A (en) * 1996-07-02 2000-05-16 Roche Diagnostics Corporation Reagents for lysergic acid diethylamide immunoassay
KR100538388B1 (en) * 1996-09-30 2005-12-22 지노버 리서치 리미티드 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
SE9801923D0 (en) * 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US6669937B2 (en) * 2000-04-20 2003-12-30 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
US7202348B2 (en) * 2000-04-20 2007-04-10 The University Of Arkansas For Medical Sciences Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
AU2001255537A1 (en) * 2000-04-20 2001-11-07 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
AU2001257230B2 (en) 2000-04-24 2006-09-14 Aryx Therapeutics Ultrashort acting hypnotic barbiturates
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
MXPA04006617A (en) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Method of preparing and using a bivalent vaccine against morphine/heroin addiction.
WO2007147122A2 (en) 2006-06-15 2007-12-21 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
EP2140263B1 (en) 2007-04-20 2017-01-04 The Board of Trustees of The University of Arkansas Hapten compounds and compositions and uses thereof
US9023353B2 (en) 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) * 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3766162A (en) * 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4045420A (en) * 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US4053459A (en) * 1975-09-24 1977-10-11 Hoffmann-La Roche Inc. Antibody specific to methaqualone and its metabolites
SU792869A1 (en) * 1979-03-30 1982-03-30 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Process for producing conjugated antigenes barbituric acid-immunogenic carrier
SU1123704A1 (en) * 1983-04-08 1984-11-15 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Method of obtaining conjugated antigens
DE3884731D1 (en) * 1987-10-09 1993-11-11 Ube Industries Monoclonal antibody to methamphetamine, its manufacture, test method and kit for methamphetamine.
EP0363041A1 (en) * 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine

Also Published As

Publication number Publication date
DE59107814D1 (en) 1996-06-20
EP0496839A1 (en) 1992-08-05
CH678394A5 (en) 1991-09-13
CA2067205C (en) 2009-10-27
WO1992003163A1 (en) 1992-03-05
ATE137977T1 (en) 1996-06-15
EP0496839B2 (en) 2004-03-03
EP0496839B1 (en) 1996-05-15
AU7050091A (en) 1992-03-17
JPH05502871A (en) 1993-05-20

Similar Documents

Publication Publication Date Title
CA2067205A1 (en) Vaccine and immune serum against drugs of abuse
EP1857121A3 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
EP1782837A3 (en) Hapten-carrier conjugates for use in drug-abuse therapy (nicotine)
NZ230199A (en) Antibody drug conjugate, intermediates and pharmaceutical compositions
GB2191943B (en) Drug delivery device, its preparation and use
AU4343089A (en) Capsular polysaccharide adhesin antigen, preparation, purification and use
HK1011025A1 (en) 5,11-Dihydro-6h-dipyrido¬3,2-b:2'3'-e¾¬1,4¾diazepines and their use in the preventionor treatment of hiv infection
CA2182289A1 (en) Immuno-stimulatory monoclonal antibodies
CA2168583A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
CA2216658A1 (en) Hapten-carrier conjugates for use in drug-abuse therapy
EP1375511A3 (en) Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
FR2667317B1 (en) 2-AMINOPYRIMIDINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
NO892057D0 (en) PSYLLIUM PREPARATION AND PROCEDURE FOR PREPARING IT.
CA2213798A1 (en) Method for stimulating an immune response
FR2735475B1 (en) N - ((1,4-DIAZABICYCLO (2.2.2) OCT-2-YL) METHYL) BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
FR2758329B1 (en) BORONIC IMIDAZOLE-4-BUTANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
IL93749A0 (en) Quinoline derivatives,their preparation and medicaments comprising them
FR2638747B1 (en) PHENYLOXYPROPANOLAMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
AU6118090A (en) N,n'-bis-1,3,5-triazin-6-ylpiperazines, and process for their preparation
FR2606409B1 (en) IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EP0419157A3 (en) Pharmacologically active compound., preparation and use
AU2065488A (en) The preparation of antigens of human immunodeficiency virus type 1, and the use thereof as diagnostic and therapeutic agent
AU7111587A (en) Perhydrothiazepine and perhydroazepine derivatives,their preparation and their therapeutic use
FR2769629B1 (en) 8-AZABICYCLO [3.2.1] OCTANE-3-METHANAMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry